Wellbeing Digital Subsidiary KGK Science to Participate at the Mushroom Summit and Psychedelic Science Conference Jun 19, 2023 04:30PM
Wellbeing Digital Enters into Share Purchase Agreement with Cardinal Group Jun 16, 2023 04:30PM
Wellbeing Digital Subsidiary KGK Science to Participate at the Nutrition Industry Association Spring Conference May 25, 2023 04:15PM
Wellbeing Subsidiary KGK Science Begins Recruitment in First-of-its-Kind Health Canada Approved Psilocybin Trial Apr 18, 2023 08:30AM
Wellbeing Subsidiary KGK Science Receives Institutional Review Board Approval Apr 11, 2023 08:30AM
View Older Stories

Apr 6, 2023 04:15PM Wellbeing Announces Cease Trade Order
Mar 16, 2023 04:30PM Wellbeing Provides Bi-Weekly Default Status Report
Mar 16, 2023 08:30AM Wellbeing Digital to Participate at the Benzinga Psychedelic Capital Conference
Mar 13, 2023 08:30AM Wellbeing Digital to Participate at the Cantor Fitzgerald Virtual Panel Discussion
Mar 9, 2023 08:30AM Wellbeing Digital to Participate in The Global Biomedical Design Conference
Mar 8, 2023 08:30AM Wellbeing Subsidiary KGK Science Applies for a Controlled Substances Dealers License and Receives Approval to Proceed with Buildout
Mar 2, 2023 04:30PM Wellbeing Provides Bi-Weekly Default Status Report
Mar 1, 2023 08:30AM Wellbeing Digital to Participate in MarigoldLIVE: International Women’s Day Networking Event
Feb 16, 2023 05:32PM Wellbeing Provides Bi-Weekly Default Status Report
Feb 15, 2023 08:30AM Wellbeing Subsidiary KGK Science Announces Publication of Safety Studies on Paraxanthine and Comparison to Caffeine Toxicity.
Feb 14, 2023 08:30AM Wellbeing Subsidiary KGK Science Receives Exemption Under Section 56 of the Controlled Drugs and Substances Act to Begin Psilocybin Clinical Trial
Feb 1, 2023 08:31AM Wellbeing Announces Delay in Filing Its Financial Statements and Management Cease Trade Order
Jan 25, 2023 08:30AM Wellbeing Digital to Participate in the Psychedelic Medicine Association Webinar
Jan 18, 2023 04:21PM Wellbeing Digital Announces Change of Auditor
Dec 22, 2022 04:15PM Wellbeing Subsidiary KGK Science Receives Approval for First-of-its-Kind Psylocibin Clinical Trial
Dec 8, 2022 08:10AM Wellbeing Subsidiary KGK Science Awarded Cannabis Research License from Health Canada
Dec 6, 2022 07:30AM Wellbeing Subsidiary KGK Science Announces Successful Results of UP446, a Nutraceutical Ingredient, in Positive Immune Defense Response
Nov 30, 2022 08:30AM Wellbeing Subsidiary KGK Science Submits CTA for Phase IIA Clinical Trial
Nov 29, 2022 07:30AM Wellbeing Subsidiary Mindscape Treats its 1,000th Patient
Nov 22, 2022 05:17PM Wellbeing Digital Announces the Appointment of Mohammad Sharifi to Board of Directors
Nov 18, 2022 04:30PM Wellbeing Digital Announces Resignation of Directors
Nov 17, 2022 08:30AM Wellbeing Subsidiary KGK Science Enters into Research Contract With Nova Mentis for Phase II A Clinical Trial
Nov 14, 2022 07:30AM Wellbeing Subsidiary KGK Science Announces Successful Delivery of CBD and THC Through the Skin of Healthy Volunteers
Nov 2, 2022 07:30AM Wellbeing Digital Subsidiary KGK to Participate in Microdose Wonderland Miami Conference
Oct 27, 2022 07:30AM Wellbeing Announces Definitive Agreement to Divest IRP Health
Oct 25, 2022 07:30AM Wellbeing Digital to Participate at this Years’ Wonderland Miami Conference
Oct 13, 2022 07:30AM Wellbeing Digital Subsidiary KGK to Participate in the Supply Side West Conference
Oct 11, 2022 07:30AM Wellbeing Digital and Subsidiary KGK Science Applauds the Government of Alberta’s Move to Regulate the Use of Psychedelics
Oct 6, 2022 07:55AM Wellbeing Subsidiary KGK Science Announces Psilocybin Microdose Capsule Formulation to be Submitted to Health Canada for Phase 2A Trial
Oct 4, 2022 07:30AM Wellbeing Digital Signs LOI Manage Additional Clinics
Sep 29, 2022 07:30AM Wellbeing Digital to Participate in the Cantor Fitzgerald Symposium on Mental Health Clinics
Sep 26, 2022 07:30AM Wellbeing Subsidiary KGK Science Opens New Clinical Research Center to Reimagine a Healthier Future
Sep 23, 2022 07:30AM Wellbeing Digital to Participate in the Microdose Psychedelic Capital Conference
Sep 15, 2022 07:49AM Wellbeing Digital Reports Financial Results for the Fourth Fiscal Quarter
Aug 30, 2022 07:30AM Wellbeing’ CEO Joins Benzinga’s Psychedelic Advisory Board
Aug 25, 2022 07:30AM Wellbeing Subsidiary KGK Science Announces AKL No Objection Status for ProGo® Branded Ingredient from FDA
Aug 23, 2022 07:30AM Wellbeing Subsidiary IRP Health Toronto Location Approved by Veterans Affairs Canada for Its Reactivation Program
Aug 18, 2022 07:30AM Wellbeing Corporate Update in a Letter from the CEO to its Shareholders
Jul 20, 2022 04:15PM Wellbeing Subsidiary KGK Science Enters Into Research Contract With Halucenex for Phase II Clinical Trial
Jun 17, 2022 07:30AM Wellbeing subsidiary KGK Science Announces Positive Clinical Trial Results of GJ 191 (JointAlive®) Supplementation in treating OA
Apr 19, 2022 10:01AM Wellbeing Digital Sciences Provides Commercial and Corporate Updates for KGK Science
Feb 15, 2022 03:00AM Wellbeing Digital Sciences Delivers its First IV Ketamine Treatment Under the Inpatient KITE Program
Jan 24, 2022 03:00AM Ketamine One Changes Name to Wellbeing Digital Sciences
Jan 17, 2022 03:00AM Ketamine One Becomes Exclusive Ketamine Treatment Provider to Victoria Wellness
Jan 12, 2022 03:00AM Ketamine One Begins Trading on the OTCQB Marketplace on January 12, 2022
Jan 10, 2022 03:00AM Ketamine One Subsidiary KGK Science Becomes the First Founding Sponsor of the “Psychedelic Science 2023” Event
Jan 5, 2022 03:00AM Ketamine One Appoints Two New Members to Its Medical Advisory Board
Dec 20, 2021 11:11AM Ketamine One Announces 2021 AGSM Results
Dec 16, 2021 03:00AM Ketamine One Reports Strong 1Q22 Financial Results
Dec 15, 2021 07:00AM Ketamine One Announces Lifting of Management Cease Trade Order
View Older Stories